Global Opioid Induced Constipation Drug Market Overview:
Global Opioid Induced Constipation Drug Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Opioid Induced Constipation Drug Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Opioid Induced Constipation Drug involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Opioid Induced Constipation Drug Market:
The Opioid Induced Constipation Drug Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Opioid Induced Constipation Drug Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Opioid Induced Constipation Drug Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Opioid Induced Constipation Drug market has been segmented into:
Agonists
Partial Agonists
Mixed Agonists/Antagonists
Antagonists
By Application, Opioid Induced Constipation Drug market has been segmented into:
Peripherally Acting -Opioid Receptor Antagonists
Peripherally Acting Non-Opioid Receptor Agonists
Centrally Acting Laxatives
Osmotic Laxatives
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Opioid Induced Constipation Drug market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Opioid Induced Constipation Drug market.
Top Key Players Covered in Opioid Induced Constipation Drug market are:
Salix Pharmaceuticals
Mallinckrodt
AstraZeneca
Intec Pharma
Impel NeuroPharma
Cosmo Pharmaceuticals
Xeris Pharmaceuticals
Synergy Pharmaceuticals
Purdue Pharma
Akcea Therapeutics
Reliant Pharmaceuticals
Braintree Laboratories
BioDelivery Sciences International
Cara Therapeutics
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Opioid Induced Constipation Drug Market Type
4.1 Opioid Induced Constipation Drug Market Snapshot and Growth Engine
4.2 Opioid Induced Constipation Drug Market Overview
4.3 Agonists
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Agonists: Geographic Segmentation Analysis
4.4 Partial Agonists
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Partial Agonists: Geographic Segmentation Analysis
4.5 Mixed Agonists/Antagonists
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Mixed Agonists/Antagonists: Geographic Segmentation Analysis
4.6 Antagonists
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Antagonists: Geographic Segmentation Analysis
Chapter 5: Opioid Induced Constipation Drug Market Application
5.1 Opioid Induced Constipation Drug Market Snapshot and Growth Engine
5.2 Opioid Induced Constipation Drug Market Overview
5.3 Peripherally Acting -Opioid Receptor Antagonists
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Peripherally Acting -Opioid Receptor Antagonists: Geographic Segmentation Analysis
5.4 Peripherally Acting Non-Opioid Receptor Agonists
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Peripherally Acting Non-Opioid Receptor Agonists: Geographic Segmentation Analysis
5.5 Centrally Acting Laxatives
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Centrally Acting Laxatives: Geographic Segmentation Analysis
5.6 Osmotic Laxatives
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.6.3 Osmotic Laxatives: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Opioid Induced Constipation Drug Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 SALIX PHARMACEUTICALS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 MALLINCKRODT
6.4 ASTRAZENECA
6.5 INTEC PHARMA
6.6 IMPEL NEUROPHARMA
6.7 COSMO PHARMACEUTICALS
6.8 XERIS PHARMACEUTICALS
6.9 SYNERGY PHARMACEUTICALS
6.10 PURDUE PHARMA
6.11 AKCEA THERAPEUTICS
6.12 RELIANT PHARMACEUTICALS
6.13 BRAINTREE LABORATORIES
6.14 BIODELIVERY SCIENCES INTERNATIONAL
6.15 CARA THERAPEUTICS
Chapter 7: Global Opioid Induced Constipation Drug Market By Region
7.1 Overview
7.2. North America Opioid Induced Constipation Drug Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Agonists
7.2.2.2 Partial Agonists
7.2.2.3 Mixed Agonists/Antagonists
7.2.2.4 Antagonists
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Peripherally Acting -Opioid Receptor Antagonists
7.2.3.2 Peripherally Acting Non-Opioid Receptor Agonists
7.2.3.3 Centrally Acting Laxatives
7.2.3.4 Osmotic Laxatives
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Opioid Induced Constipation Drug Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Agonists
7.3.2.2 Partial Agonists
7.3.2.3 Mixed Agonists/Antagonists
7.3.2.4 Antagonists
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Peripherally Acting -Opioid Receptor Antagonists
7.3.3.2 Peripherally Acting Non-Opioid Receptor Agonists
7.3.3.3 Centrally Acting Laxatives
7.3.3.4 Osmotic Laxatives
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Opioid Induced Constipation Drug Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Agonists
7.4.2.2 Partial Agonists
7.4.2.3 Mixed Agonists/Antagonists
7.4.2.4 Antagonists
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Peripherally Acting -Opioid Receptor Antagonists
7.4.3.2 Peripherally Acting Non-Opioid Receptor Agonists
7.4.3.3 Centrally Acting Laxatives
7.4.3.4 Osmotic Laxatives
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Opioid Induced Constipation Drug Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Agonists
7.5.2.2 Partial Agonists
7.5.2.3 Mixed Agonists/Antagonists
7.5.2.4 Antagonists
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Peripherally Acting -Opioid Receptor Antagonists
7.5.3.2 Peripherally Acting Non-Opioid Receptor Agonists
7.5.3.3 Centrally Acting Laxatives
7.5.3.4 Osmotic Laxatives
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Opioid Induced Constipation Drug Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Agonists
7.6.2.2 Partial Agonists
7.6.2.3 Mixed Agonists/Antagonists
7.6.2.4 Antagonists
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Peripherally Acting -Opioid Receptor Antagonists
7.6.3.2 Peripherally Acting Non-Opioid Receptor Agonists
7.6.3.3 Centrally Acting Laxatives
7.6.3.4 Osmotic Laxatives
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Opioid Induced Constipation Drug Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Agonists
7.7.2.2 Partial Agonists
7.7.2.3 Mixed Agonists/Antagonists
7.7.2.4 Antagonists
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Peripherally Acting -Opioid Receptor Antagonists
7.7.3.2 Peripherally Acting Non-Opioid Receptor Agonists
7.7.3.3 Centrally Acting Laxatives
7.7.3.4 Osmotic Laxatives
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Opioid Induced Constipation Drug Scope:
|
Report Data
|
Opioid Induced Constipation Drug Market
|
|
Opioid Induced Constipation Drug Market Size in 2025
|
USD XX million
|
|
Opioid Induced Constipation Drug CAGR 2025 - 2032
|
XX%
|
|
Opioid Induced Constipation Drug Base Year
|
2024
|
|
Opioid Induced Constipation Drug Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Salix Pharmaceuticals, Mallinckrodt, AstraZeneca, Intec Pharma, Impel NeuroPharma, Cosmo Pharmaceuticals, Xeris Pharmaceuticals, Synergy Pharmaceuticals, Purdue Pharma, Akcea Therapeutics, Reliant Pharmaceuticals, Braintree Laboratories, BioDelivery Sciences International, Cara Therapeutics.
|
|
Key Segments
|
By Type
Agonists
Partial Agonists
Mixed Agonists/Antagonists
Antagonists
By Applications
Peripherally Acting -Opioid Receptor Antagonists
Peripherally Acting Non-Opioid Receptor Agonists
Centrally Acting Laxatives
Osmotic Laxatives
|
